Lilly Breathing Down Amgen/Novartis's Necks With Three Phase III Migraine Wins

Lilly will seek FDA approval in the second half of 2017 for CGRP inhibitor galcanezumab based on three positive Phase III studies – within months of a filing for Amgen's and Novartis's CGRP inhibitor erenumab.